Literature DB >> 17724708

The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence.

Jeong Won Jang1, Jong Young Choi, Si Hyun Bae, Seung Kew Yoon, Hyun Young Woo, U Im Chang, Chang Wook Kim, Soon Woo Nam, Se Hyun Cho, Jin Mo Yang, Chang Don Lee.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) has a high tendency for recurrence after radical treatment. Apart from tumor and liver function parameters, little is known about the role of hepatitis B virus (HBV) factors in the recurrence of HCC. The objective of this study was to identify the potential relation between viral load and HCC recurrence in patients undergoing transarterial chemolipiodolization.
METHODS: This was a cohort study of 62 consecutive patients who had HBV-related HCC and achieved complete necrosis with transarterial chemolipiodolization. Risk factors, including viral load for posttreatment recurrence, were analyzed.
RESULTS: Overall, 32 of 62 patients (51.6%) developed a recurrence during the study period (7.2-37.5 months). Multivariate analysis established Child-Pugh Class B (P = .014), multiple tumors (P = .013), and high viral load (HBV DNA levels >10(5) copies/mL) at complete necrosis (P = .001) as independent risk factors for recurrence. On both univariate and multivariate analyses, high viral load at the time of complete necrosis was identified as the strongest factor for recurrence; moreover, its statistically significant effects still were observed even when conducting the analyses separately for both local recurrence (P = .018) and distant recurrence (P = .009).
CONCLUSIONS: Among individuals who underwent transarterial chemolipiodolization, high HBV viral load at complete necrosis was among the most important risk factors for posttreatment recurrence, irrespective of the locational pattern of recurrence. The current findings underscored the need for future work that tests the applicability of antiviral therapy to reduce the risk of HCC recurrence in this setting.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724708     DOI: 10.1002/cncr.22984

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Clinical features of hepatitis B virus-related hepatocellular carcinoma.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

2.  Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

Authors:  Chuan Chen; Dong-Ping Chen; Yan-Yan Gu; Liang-Hao Hu; Dan Wang; Jin-Huan Lin; Zhao-Shen Li; Jing Xu; Ge Wang
Journal:  Tumour Biol       Date:  2015-04-02

Review 3.  Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment.

Authors:  Xiao-Jun Lin; Xiang-Ming Lao; Ming Shi; Sheng-Ping Li
Journal:  Dig Dis Sci       Date:  2016-04-22       Impact factor: 3.199

Review 4.  Hepatitis B viral load affects prognosis of hepatocellular carcinoma.

Authors:  Su Jong Yu; Yoon Jun Kim
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 5.  Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma.

Authors:  Yi-Fang Han; Jun Zhao; Li-Ye Ma; Jian-Hua Yin; Wen-Jun Chang; Hong-Wei Zhang; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2011-10-14       Impact factor: 5.742

Review 6.  Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy.

Authors:  Il Han Song; So Mi Kim; Young Kwang Choo
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

7.  The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma.

Authors:  Makoto Chuma; Shuhei Hige; Toshiya Kamiyama; Takashi Meguro; Atsushi Nagasaka; Kazuaki Nakanishi; Yoshiya Yamamoto; Mitsuru Nakanishi; Toshihisa Kohara; Takuya Sho; Keiko Yamamoto; Hiromasa Horimoto; Tomoe Kobayashi; Hideki Yokoo; Michiaki Matsushita; Satoru Todo; Masahiro Asaka
Journal:  J Gastroenterol       Date:  2009-06-25       Impact factor: 7.527

8.  The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma.

Authors:  Liang-He Yu; Nan Li; Shu-Qun Cheng
Journal:  Int J Hepatol       Date:  2011-05-30

9.  Genotypes, mutations, and viral load of hepatitis B virus and the risk of hepatocellular carcinoma: HBV properties and hepatocarcinogenesis.

Authors:  Qi Zhang; Guangwen Cao
Journal:  Hepat Mon       Date:  2011-02       Impact factor: 0.660

10.  Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization.

Authors:  Suk Kyeong Ji; Yun Ku Cho; Yong Sik Ahn; Mi Young Kim; Yoon Ok Park; Jae Kyun Kim; Wan Tae Kim
Journal:  Korean J Radiol       Date:  2008 Nov-Dec       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.